Le Lézard
Classified in: Health, Business, Covid-19 virus
Subjects: ERN, ERP

Envista Reports Third Quarter 2023 Earnings


BREA, Calif., Nov. 1, 2023 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the third quarter 2023. 

For the quarter ended September 29, 2023, reported sales were $631.3 million.  Core sales in the quarter increased 0.8% over the corresponding quarter in 2022.

Net income in the third quarter of 2023 was $21.5 million or $0.12 per diluted share.  During the same period, adjusted net income was $75.5 million or $0.43 per diluted share compared to adjusted net income of $82.5 million or $0.47 per diluted share in the same period of 2022.  Adjusted EBITDA in the quarter was $123.5 million compared to $127.6 million in the third quarter of 2022. 

Amir Aghdaei, Chief Executive Officer, stated, "In the third quarter, we delivered positive core growth and an adjusted EBITDA margin of 19.6%.  Our Specialty Product & Technology Segment delivered low-single digit core growth as Spark outperformed, overcoming the negative impact of both Russia and the continued weakness of higher end specialty procedures in developed markets.  Our Equipment & Consumables segment declined low-single digit, as solid core growth in consumables was offset by the planned rationalization of our traditional imaging portfolio.  We continue to utilize the Envista Business System (EBS) to streamline our operations and improve our cost position, delivering 50 bps of sequential margin improvement in the quarter." 

Mr. Aghdaei continued, "While we remain confident in our ability to execute our long-term strategy, we are revising our full year guidance for 2023 to reflect the increased macro uncertainty and the importance of making investments to drive our long-term strategy of accelerating growth, expanding margins, and transforming our portfolio."

2023 Guidance

Due to the continued uncertainties in the macro environment, volatility in the North American distribution channel and our continued investment in our long-term growth initiatives, we now expect full year core sales to be down slightly and adjusted EBITDA margin to be between 18% to 19%.

Please note, we do not provide forward-looking estimates on a GAAP basis as certain information is not available and cannot be reasonably estimated. 

Envista will discuss its quarterly results during an investor conference call today starting at 2:00 P.M. PT.  The call and an accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of Envista's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing +1 (800) 267-6316 within the U.S. or +1 (203) 518-9783 outside the U.S. a few minutes before 2:00 PM PT and referencing conference ID #8206745.  A replay of the conference call will be available shortly after the conclusion of the call.  You can access the replay dial-in information on the "Investors" section of Envista's website under the subheading "Events & Presentations." Presentation materials relating to Envista's results have been posted to the "Investors" section of Envista's website under the subheading "Quarterly Earnings." 

ABOUT ENVISTA

Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.

NON-GAAP MEASURES

All "Adjusted" amounts including core sales growth and free cash flow are non-GAAP items. Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these non-GAAP measures are included in the attached supplemental schedules. We do not reconcile forward looking non-GAAP measures to the comparable GAAP measures because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation, acquisitions, discontinued products, and any other potential adjustments which would be reflected in any forecasted GAAP measure. 

FORWARD-LOOKING STATEMENTS

Certain statements in this press release are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the conditions in the U.S. and global economy, the impact of inflation and increasing interest rates, international economic, political, legal, compliance and business factors, the markets served by us and the financial markets, the impact of the COVID-19 pandemic, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in trade policies and regulations, contractions or growth rates and cyclicality of markets we serve, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, disruptions relating to war, terrorism, climate change, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events, security breaches or other disruptions of our information technology systems or violations of data privacy laws, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, our ability to attract, develop and retain our key personnel, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, the impact of regulation on demand for our products and services, and labor matters. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for fiscal year 2022 and our Quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release and except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.     

CONTACT
Stephen Keller
Principal Financial Officer
Envista Holdings Corporation
200 S. Kraemer Blvd., Building E
Brea, CA 92821
Telephone: (714) 817-7000
Fax: (714) 817-5450    

 

ENVISTA HOLDINGS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

($ and shares in millions, except per share amounts)



Three Months Ended


Nine Months Ended


September 29, 2023


September 30, 2022


September 29, 2023


September 30, 2022

Sales

$                  631.3


$                  631.1


$               1,920.9


$               1,908.3

Cost of sales

268.0


266.4


816.3


799.7

Gross profit

363.3


364.7


1,104.6


1,108.6

Operating expenses:








Selling, general and administrative

257.7


264.2


796.7


801.9

Research and development

22.3


26.0


73.6


75.5

Operating profit

83.3


74.5


234.3


231.2

Nonoperating (expense) income:








Other (expense) income

(32.1)


0.3


(24.7)


0.9

Interest expense, net

(15.4)


(11.6)


(49.5)


(23.9)

Income before income taxes

35.8


63.2


160.1


208.2

Income tax expense

14.3


13.6


42.9


43.7

Income from continuing operations, net of tax

21.5


49.6


117.2


164.5

(Loss) Income from discontinued
operations, net of tax

?


(2.0)


?


5.1

Net income

$                     21.5


$                    47.6


$                  117.2


$                   169.6

Earnings per share:








Earnings from continuing operations - basic

$                     0.13


$                    0.30


$                    0.71


$                     1.01

Earnings from continuing operations - diluted

$                     0.12


$                    0.28


$                    0.66


$                     0.92









(Loss) Earnings from discontinued
operations - basic

$                        ?


$                  (0.01)


$                        ?


$                     0.03

(Loss) Earnings from discontinued
operations - diluted

$                        ?


$                  (0.01)


$                        ?


$                     0.03









Earnings - basic

$                     0.13


$                    0.29


$                    0.71


$                     1.04

Earnings - diluted

$                     0.12


$                    0.27


$                    0.66


$                     0.95

Average common stock and common
equivalent shares outstanding:








Basic

168.2


163.1


165.3


162.7

Diluted

175.2


176.9


176.3


178.4

 

ENVISTA HOLDINGS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

($ in millions, except share amounts)



As of


September 29, 2023


December 31, 2022

ASSETS




Current assets:




Cash and cash equivalents

$                    824.2


$                 606.9

     Trade accounts receivable, less allowance for credit losses of $16.0 and $16.2,
respectively

417.1


393.5

Inventories, net

278.8


300.8

Prepaid expenses and other current assets

120.6


123.4

Total current assets

1,640.7


1,424.6

Property, plant and equipment, net

304.0


293.6

Operating lease right-of-use assets

126.6


131.8

Other long-term assets

152.9


153.7

Goodwill

3,458.2


3,496.6

Other intangible assets, net

1,001.4


1,086.7

Total assets

$                 6,683.8


$             6,587.0

LIABILITIES AND EQUITY




Current liabilities:




Short-term debt

$                    115.1


$                 510.0

Trade accounts payable

168.6


228.3

Accrued expenses and other liabilities

433.7


471.4

Operating lease liabilities

29.4


27.0

Total current liabilities

746.8


1,236.7

Operating lease liabilities

112.3


121.4

Other long-term liabilities

150.5


151.3

Long-term debt

1,381.0


870.7

Commitments and contingencies




Stockholders' equity:




Preferred stock, $0.01 par value, 15.0 million shares authorized; no shares issued
or outstanding at September 29, 2023 and December 31, 2022

?


?

Common stock - $0.01 par value, 500.0 million shares authorized; 173.2 million
shares issued and 171.3 million shares outstanding at September 29, 2023; 163.7
million shares issued and 163.2 million shares outstanding at December 31, 2022

1.7


1.6

Additional paid-in capital

3,749.7


3,699.0

Retained earnings

848.6


731.4

Accumulated other comprehensive loss

(306.8)


(225.1)

Total stockholders' equity

4,293.2


4,206.9

Total liabilities and stockholders' equity

$                 6,683.8


$             6,587.0

 

ENVISTA HOLDINGS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

($ in millions)



Nine Months Ended


September 29, 2023


September 30, 2022

Cash flows from operating activities:




Net income

$                    117.2


$                    169.6

Noncash items:




Depreciation

26.8


23.9

Amortization

75.9


78.2

Allowance for credit losses

3.5


3.8

Stock-based compensation expense

26.2


23.1

Gain on equity investments, net

(3.6)


?

Gain on sale of property, plant and equipment

(2.0)


(1.1)

Gain on sale of KaVo treatment unit and instrument business

?


(8.9)

Restructuring charges

0.7


5.5

Impairment charges

0.3


5.8

Fair value adjustment of acquisition-related inventory

?


7.7

Amortization of right-of-use assets

19.9


17.7

Inducement expense related to exchange of convertible notes

28.5


?

Amortization of debt discount and issuance costs

3.4


3.0

Change in trade accounts receivable

(33.0)


(76.5)

Change in inventories

9.4


(35.9)

Change in trade accounts payable

(53.2)


11.3

Change in prepaid expenses and other assets

5.4


(21.7)

Change in accrued expenses and other liabilities

(26.1)


(109.7)

Change in operating lease liabilities

(25.6)


(23.4)

Net cash provided by operating activities

173.7


72.4

Cash flows from investing activities:




Payments for additions to property, plant and equipment

(50.0)


(58.8)

Proceeds from sales of property, plant and equipment

?


1.6

Proceeds from sale of equity investment

10.7


?

Acquisitions, net of cash acquired

?


(696.2)

Proceeds from sale of KaVo treatment unit and instrument business, net

?


59.8

Proceeds from the settlement of derivative financial instruments

1.1


55.9

All other investing activities, net

(11.6)


(18.5)

Net cash used in investing activities

(49.8)


(656.2)

Cash flows from financing activities:




Proceeds from issuance of convertible notes due 2028

500.2


?

Debt issuance costs related to issuance of convertible notes due 2028

(13.5)


?

Principal paid related to exchange of convertible notes due 2025

(401.2)


?

Proceeds from borrowings

323.5


0.3

Repayment of borrowings

(288.8)


(0.5)

Debt issuance costs related to other borrowings

(4.5)


?

Proceeds from revolving line of credit

?


124.0

Repayment of revolving line of credit

?


(54.0)

Proceeds from stock option exercises

7.5


19.9

Tax withholding payment related to net settlement of equity awards

(7.8)


(8.9)

All other financing activities

0.2


?

Net cash provided by financing activities

115.6


80.8

Effect of exchange rate changes on cash and cash equivalents

(22.2)


(2.1)

Net change in cash and cash equivalents

217.3


(505.1)

Beginning balance of cash and cash equivalents

606.9


1,073.6

Ending balance of cash and cash equivalents

$                    824.2


$                    568.5

 

ENVISTA HOLDINGS CORPORATION

SUMMARY OF FINANCIAL METRICS (Unaudited)

($ in millions, except per share amounts)



GAAP


Three Months Ended


Nine Months Ended


September 29, 2023


September 30, 2022


September 29, 2023


September 30, 2022

Gross Profit

$                   363.3


$                   364.7


$          1,104.6


$          1,108.6

Operating Profit From Continuing Operations

$                     83.3


$                     74.5


$             234.3


$             231.2

Net Income From Continuing Operations

$                     21.5


$                     49.6


$             117.2


$             164.5

Diluted EPS From Continuing Operations

$                     0.12


$                     0.28


$                0.66


$                0.92

Operating Cash Flow

$                     95.5


$                     46.7


$             173.7


$                72.4



NON-GAAP *


Three Months Ended


Nine Months Ended


September 29, 2023


September 30, 2022


September 29, 2023


September 30, 2022

Adjusted Gross Profit

$                   364.3


$                   373.5


$          1,111.9


$          1,126.3

Adjusted Operating Profit

$                   114.4


$                   119.5


$             336.2


$             354.3

Adjusted Net Income

$                      75.5


$                     82.5


$             219.5


$             253.4

Adjusted Diluted EPS

$                      0.43


$                     0.47


$                1.25


$                1.42

Adjusted EBITDA

$                   123.5


$                   127.6


$             363.7


$             379.1

Free Cash Flow

$                      77.1


$                     19.7


$             123.7


$                15.2


 * For information on non-GAAP measures see "Reconciliation of GAAP to Non-GAAP Financial Measures" below. Also see the accompanying "Notes to Reconciliation of GAAP to Non-GAAP Financial Measures."

 

ENVISTA HOLDINGS CORPORATION

SEGMENT INFORMATION (Unaudited)

($ in millions)



Three Months Ended


Nine Months Ended


September 29, 2023


September 30, 2022


September 29, 2023


September 30, 2022

Sales








Specialty Products & Technologies

$                  399.5


$                  395.4


$          1,226.5


$          1,200.2

Equipment & Consumables

231.8


235.7


694.4


708.1

Total

$                  631.3


$                  631.1


$          1,920.9


$          1,908.3









Operating Profit (Loss)








Specialty Products & Technologies

$                    61.4


$                    62.3


$             188.2


$             206.6

Equipment & Consumables

43.9


44.7


124.8


120.4

Other

(22.0)


(32.5)


(78.7)


(95.8)

Total

$                    83.3


$                    74.5


$             234.3


$             231.2









Operating Margins








Specialty Products & Technologies

15.4 %


15.8 %


15.3 %


17.2 %

Equipment & Consumables

18.9 %


19.0 %


18.0 %


17.0 %

Total

13.2 %


11.8 %


12.2 %


12.1 %

 

ENVISTA HOLDINGS CORPORATION

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)

($ in millions, except per share amounts)


Adjusted Gross Profit and Adjusted Gross Margin



Three Months Ended


Nine Months Ended


September 29,
2023


September 30,
2022


September 29,
2023


September 30,
2022

Gross Profit

$          363.3


$          364.7


$       1,104.6


$      1,108.6

Restructuring costs and asset impairments A

1.0


3.4


7.3


10.0

    Fair value adjustment of acquisition-related inventory C 

?


5.4


?


7.7

Adjusted Gross Profit

$          364.3


$          373.5


$       1,111.9


$      1,126.3









Gross Margin (Gross Profit / Sales)

57.5 %


57.8 %


57.5 %


58.1 %

Adjusted Gross Margin (Adjusted Gross Profit / Sales)

57.7 %


59.2 %


57.9 %


59.0 %


Adjusted Operating Profit 

Three Months Ended


Nine Months Ended


September 29,
2023


September 30,
2022


September 29,
2023


September 30,
2022

Consolidated








Operating Profit

$             83.3


$            74.5


$          234.3


$          231.2

Amortization of acquisition-related and other intangible assets

23.9


27.9


75.9


78.2

Restructuring costs and asset impairments A

6.8


9.6


24.7


28.1

Acquisition related expenses B

0.4


2.1


1.3


14.6

    Fair value adjustment of acquisition-related inventory C 

?


5.4


?


7.7

Contingent loss reserves F

?


?


?


1.0

International tax credit G

?


?


?


(6.5)

Adjusted Operating Profit

$          114.4


$          119.5


$          336.2


$          354.3

Adjusted Operating Profit as a % of Sales

18.1 %


18.9 %


17.5 %


18.6 %









Specialty Products & Technologies








Operating Profit

$             61.4


$            62.3


$          188.2


$          206.6

Amortization of acquisition-related and other intangible assets

15.7


15.4


47.3


44.7

Restructuring costs and asset impairments A

1.7


4.5


9.5


12.7

Contingent loss reserves F

?


?


?


1.0

International tax credit G

?


?


?


(1.7)

Adjusted Operating Profit

$             78.8


$            82.2


$          245.0


$          263.3

Adjusted Operating Profit as a % of Sales

19.7 %


20.8 %


20.0 %


21.9 %









Equipment & Consumables








Operating Profit

$             43.9


$            44.7


$          124.8


$          120.4

Amortization of acquisition-related and other intangible assets

8.2


12.5


28.6


33.5

Restructuring costs and asset impairments A

5.0


4.2


14.0


12.6

International tax credit G

?


?


?


(4.8)

Adjusted Operating Profit

$             57.1


$            61.4


$          167.4


$          161.7

Adjusted Operating Profit as a % of Sales

24.6 %


26.1 %


24.1 %


22.8 %


See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures 


Adjusted Net Income



Three Months Ended


Nine Months Ended


September 29,
2023


September 30,
2022


September 29,
2023


September 30,
2022

Net Income From Continuing Operations

$                21.5


$                49.6


$              117.2


$              164.5

Amortization of acquisition-related and other intangible assets

23.9


27.9


75.9


78.2

Restructuring costs and asset impairments A

6.8


9.6


24.7


28.1

Acquisition related expenses B

0.4


2.1


1.3


14.6

    Fair value adjustment of acquisition-related inventory C

?


5.4


?


7.7

Loss (gain) on equity investments, net D

3.3


?


(3.6)


?

Inducement and other expenses related to convertible notes exchange E

29.0


?


29.0


?

Contingent loss reserves F

?


?


?


1.0

International tax credit G

?


?


?


(6.5)

Tax effect of adjustments reflected above H

(10.4)


(10.4)


(25.5)


(28.4)

Discrete tax adjustments and other tax-related adjustments I

1.0


(1.7)


0.5


(5.8)

Adjusted Net Income

$                75.5


$                82.5


$              219.5


$              253.4


Adjusted Diluted Earnings Per Share



Three Months Ended


Nine Months Ended


September 29,
2023


September 30,
2022


September 29,
2023


September 30,
2022

Diluted Earnings From Continuing Operations Per Share

$                0.12


$                 0.28


$               0.66


$                0.92

Amortization of acquisition-related and other intangible assets

0.14


0.16


0.43


0.44

Restructuring costs and asset impairments A

0.04


0.05


0.14


0.16

Acquisition related expenses B

?


0.01


0.01


0.08

     Fair value adjustment of acquisition-related inventory C

?


0.03


?


0.04

Loss (gain) on equity investments, net D

0.02


?


(0.02)


?

Inducement and other expenses related to convertible notes exchange E

0.17


?


0.16


?

Contingent loss reserves F

?


?


?


0.01

International tax credit G

?


?


?


(0.04)

Tax effect of adjustments reflected above H

(0.07)


(0.05)


(0.14)


(0.16)

Discrete tax adjustments and other tax-related adjustments I

0.01


(0.01)


0.01


(0.03)

Adjusted Diluted Earnings Per Share

$                0.43


$                 0.47


$               1.25


$                1.42


Adjusted EBITDA



Three Months Ended


Nine Months Ended


September 29,
2023


September 30,
2022


September 29,
2023


September 30,
2022

Net Income From Continuing Operations

$            21.5


$            49.6


$          117.2


$         164.5

Interest expense, net

15.4


11.6


49.5


23.9

Income taxes

14.3


13.6


42.9


43.7

Depreciation

8.9


7.8


26.8


23.9

Amortization of acquisition-related and other intangible assets

23.9


27.9


75.9


78.2

Restructuring costs and asset impairments A

6.8


9.6


24.7


28.1

Acquisition related expenses B

0.4


2.1


1.3


14.6

    Fair value adjustment of acquisition-related inventory C

?


5.4


?


7.7

Loss (gain) on equity investments, net D

3.3


?


(3.6)


?

Inducement and other expenses related to convertible notes exchange E

29.0


?


29.0


?

Contingent loss reserves F

?


?


?


1.0

International tax credit G

?


?


?


(6.5)

Adjusted EBITDA

$          123.5


$          127.6


$          363.7


$         379.1

Adjusted EBITDA as a % of Sales

19.6 %


20.2 %


18.9 %


19.9 %


See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

 

Core Sales Growth 1 


Consolidated

% Change Three
Month Period Ended

September 29, 2023 vs.
Comparable 2022
Period


% Change Nine
Month Period Ended

September 29, 2023 vs.
Comparable 2022
Period

Total sales growth

? %


0.7 %

Plus the impact of:




Acquisitions

? %


(1.7) %

Currency exchange rates

0.8 %


1.2 %

Core sales growth

0.8 %


0.2 %





Specialty Products & Technologies




Total sales growth

1.0 %


2.2 %

Plus the impact of:




Acquisitions

? %


(1.4) %

Currency exchange rates

1.2 %


1.5 %

Core sales growth

2.2 %


2.3 %





Equipment & Consumables




Total sales growth

(1.7) %


(1.9) %

Plus the impact of:




Acquisitions

? %


(2.0) %

Currency exchange rates

0.1 %


0.4 %

Core sales growth

(1.6) %


(3.5) %



1

We use the term "core sales" to refer to GAAP revenue excluding (1) sales from acquired businesses recorded prior to the first anniversary of the acquisition ("acquisitions"), (2) sales from discontinued products and (3) the impact of currency translation. Sales from discontinued products includes major brands or products that Envista has made the decision to discontinue as part of a portfolio restructuring. Discontinued brands or products consist of those which Envista (1) is no longer manufacturing, (2) is no longer investing in the research or development of, and (3) expects to discontinue all significant sales within one year from the decision date to discontinue. The portion of sales attributable to discontinued brands or products is calculated as the net decline of the applicable discontinued brand or product from period-to-period. The portion of GAAP revenue attributable to currency exchange rates is calculated as the difference between (a) the period-to-period change in sales and (b) the period-to-period change in sales after applying current period foreign exchange rates to the prior year period. We use the term "core sales growth" to refer to the measure of comparing current period core sales with the corresponding period of the prior year.

 

Reconciliation of Operating Cash Flows to Free Cash Flow



Three Months Ended


Nine Months Ended


September 29,
2023


September 30,
2022


September 29,
2023


September 30,
2022

Net Operating Cash Provided by Operating Activities

$                 95.5


$                 46.7


$               173.7


$                 72.4

Less: payments for additions to property, plant and
equipment (capital expenditures)

(18.4)


(26.9)


(50.0)


(58.8)

Plus: proceeds from sales of property, plant and
equipment (capital disposals)

?


(0.1)


?


1.6

Free Cash Flow

$                 77.1


$                 19.7


$               123.7


$                 15.2


See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

 

ENVISTA HOLDINGS CORPORATION
NOTES TO RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)



A

We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements) from the ongoing productivity improvements that result from application of the Envista Business System. These restructuring plans are incremental to the operating activities that arise in the ordinary course of our business and we believe are not indicative of Envista's ongoing operating costs in a given period.



B

These represent acquisition related transactions expenses and integration costs with respect to business combinations.



C

Represents the fair value adjustment related to inventory acquired in connection with acquisitions.



D

Represents gains or losses on equity investments.



E

These costs primarily relate to inducement and other expenses incurred in connection with our partial exchange of our 2025 Convertible Senior Notes.  



F

Represents accruals for certain legal matters.



G

Represents international tax credit related to a ruling from the Brazilian Supreme Court.



H

This line item reflects the aggregate tax effect of all pretax adjustments reflected in the preceding line items of the table using each adjustment's applicable tax rate, including the effect of interim tax accounting requirements of Accounting Standards Codification Topic 740 Income Taxes.



I

The discrete tax matters relate primarily to excess tax benefits from stock-based compensation, changes in estimates associated with prior period uncertain tax positions and audit settlements, tax benefits resulting from a change in law, and changes in determination of realization of certain deferred tax assets.

 

Statement Regarding Non-GAAP Measures

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Envista Holdings Corporation's ("Envista" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors to:

Management uses these non-GAAP measures to measure the Company's operating and financial performance.

The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:

 

SOURCE Envista Holdings Corporation


These press releases may also interest you

at 08:50
E Split Corp. (the "Fund") is pleased to announce that a distribution for February 2024 will be payable to Class A shareholders of E Split Corp. as follows: Record Date Payable DateDistribution Per Equity ShareFebruary 29, 2024March 15,...

at 08:50
Real Estate Split Corp. (the "Fund") is pleased to announce that a distribution for February 2024 will be payable to Class A shareholders of Real Estate Split Corp. as follows: Record Date Payable DateDistribution PerEquity ShareFebruary 29,...

at 08:48
As part of the global GSMA Open Gateway initiative, South African operators will now be able to implement world-class Number Verification and SIM Swap ? Application Programme Interfaces (APIs) ? to coincide...

at 08:48
Tinsley Medical Practice Brokers, led by Managing Director and Co-Founder Sean Tinsley, assisted Forum Health, LLC, a pioneering multi-location Integrative and Functional Medicine practice at the forefront of holistic healthcare, in taking their...

at 08:48
Succession Link, the premier M&A networking and communication platform for financial professionals, announced it has signed an agreement with Commonwealth Financial Network®, a national firm dedicated to providing financial advisors with holistic,...

at 08:45
Brightmerge, a leading innovator accelerating the transition to electrified fleets, announced today the release of an advanced version of the Brightmerge business performance optimization platform for the sales, design, optimization and operation of...



News published on and distributed by: